[EN] NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES [FR] NOUVEAUX N-[(PYRIMIDINYLAMINO)PROPANYL]- ET N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.
This invention relates to compounds of formula (I) a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2 and R3 have meanings given in the description.
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 and Ar2 have meanings given in the description.
[EN] NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N-[(PYRIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES<br/>[FR] NOUVEAUX N-[(PYRIMIDINYLAMINO)PROPANYL]- ET N-[(PYRIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2017178343A1
公开(公告)日:2017-10-19
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
[EN] NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL] - AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES<br/>[FR] NOUVEAUX N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL] - ET N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2019025275A1
公开(公告)日:2019-02-07
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.